{"id":"ranibizumab-deferred-laser","safety":{"commonSideEffects":[{"rate":"null","effect":"Intraocular inflammation"},{"rate":"null","effect":"Endophthalmitis"},{"rate":"null","effect":"Retinal detachment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"VEGF-A is a protein that promotes angiogenesis, the formation of new blood vessels. By inhibiting VEGF-A, ranibizumab reduces the growth of new blood vessels in the retina, which can help slow vision loss in conditions such as age-related macular degeneration.","oneSentence":"Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) by binding to its receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:17.327Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of neovascular (wet) age-related macular degeneration"},{"name":"Treatment of macular edema following retinal vein occlusion"}]},"trialDetails":[{"nctId":"NCT00444600","phase":"PHASE3","title":"Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2007-03","conditions":"Diabetic Retinopathy, Diabetic Macular Edema","enrollment":691},{"nctId":"NCT03590444","phase":"PHASE4","title":"Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser","status":"COMPLETED","sponsor":"Hospital Hietzing","startDate":"2017-04-02","conditions":"Diabetic Retinal Edema","enrollment":50},{"nctId":"NCT01823965","phase":"PHASE2","title":"Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2011-10","conditions":"Diabetic Macular Edema","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lucentis, anti-VEGF drug"],"phase":"phase_3","status":"active","brandName":"Ranibizumab + deferred laser","genericName":"Ranibizumab + deferred laser","companyName":"Jaeb Center for Health Research","companyId":"jaeb-center-for-health-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) by binding to its receptor. Used for Treatment of neovascular (wet) age-related macular degeneration, Treatment of macular edema following retinal vein occlusion.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}